As emerging biotech firm Rainbow Coral Corp. (OTCBB: RBCC) closes in on a deal with a new clinical-stage company developing diagnostics and therapeutics for Parkinson’s disease, exciting news is emerging that drugs used to treat the disease could also be beneficial to patients suffering from traumatic brain injuries.
Scientists reported last month that daily doses of a drug used to treat Parkinson’s disease significantly improved function in severely brain-injured people thought to be beyond the reach of treatment. Researchers from 11 clinics enrolled 184 patients who recently had a traumatic brain injury from a car accident or from blows to the head in the study. The program’s results, published in the New England Journal of Medicine, were highly encouraging.
Patients receiving daily doses of the Parkinson’s drug amantadine showed improvements in coordination and communication beyond those of the control group. The study could be a turning point in the understanding and treatment of people with severe traumatic brain injuries, opening up Parkinson’s treatments to a new market of thousands of patients.
RBCC is working hard to capitalize on the growing demand for effective treatments for Parkinson’s and other neurological health issues. Last week, the company initiated discussions for a term sheet with an emerging biotech firm developing a pre-clinical therapeutic protein for the treatment of Parkinson’s, traumatic brain injury and stroke.
Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).
For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.
Follow us on Twitter at www.twitter.com/RBCCinfo.
About Rainbow BioSciences
Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.